Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 149,800
+500 (0.33%)
At close: Apr 8, 2026
Daewoong Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 195,856 | 24,735 | 121,739 | 42,240 | 24,506 |
Depreciation & Amortization | 51,072 | 48,978 | 43,797 | 39,695 | 40,883 |
Loss (Gain) From Sale of Assets | -52,328 | 465.97 | -30,198 | -246.4 | 1,029 |
Asset Writedown & Restructuring Costs | 14,654 | 15,492 | 2,372 | 5,219 | 2,109 |
Loss (Gain) From Sale of Investments | 4,506 | 24,951 | -130.67 | 4,112 | -8,308 |
Loss (Gain) on Equity Investments | 6,107 | 23,153 | 1,443 | 374.54 | -257.52 |
Stock-Based Compensation | 475.96 | 545.31 | 1,618 | 1,841 | 2,005 |
Provision & Write-off of Bad Debts | 3,057 | 2,192 | 5,835 | 2,250 | 2,125 |
Other Operating Activities | 272.54 | -6,226 | 10,254 | -8,852 | 5,813 |
Change in Accounts Receivable | -8,563 | -22,597 | -478.7 | -23,193 | -20,692 |
Change in Accounts Payable | 23,294 | -16,674 | 16,597 | 12,408 | -8,373 |
Change in Other Net Operating Assets | -89,199 | -43,523 | -36,838 | 42,368 | -844.34 |
Operating Cash Flow | 149,205 | 51,492 | 136,009 | 118,215 | 39,994 |
Operating Cash Flow Growth | 189.76% | -62.14% | 15.05% | 195.58% | -60.39% |
Capital Expenditures | -191,534 | -155,145 | -109,338 | -65,227 | -29,088 |
Sale of Property, Plant & Equipment | 455.1 | 43.05 | 1,446 | 483.47 | 257.43 |
Cash Acquisitions | -2,928 | - | -5,807 | - | - |
Divestitures | - | - | 45.59 | - | - |
Sale (Purchase) of Intangibles | -49,478 | -73,858 | -46,289 | -46,826 | -45,633 |
Investment in Securities | -3,928 | -35,557 | -8,791 | 6,983 | -13,220 |
Other Investing Activities | 178.53 | -636.34 | 3,123 | 67.5 | - |
Investing Cash Flow | -247,026 | -265,451 | -165,621 | -106,872 | -87,683 |
Short-Term Debt Issued | 377,971 | 80,000 | 113,742 | 86,154 | 52,352 |
Long-Term Debt Issued | 310,548 | 325,187 | 65,000 | 149,683 | 108,357 |
Total Debt Issued | 688,519 | 405,187 | 178,742 | 235,837 | 160,709 |
Short-Term Debt Repaid | -513,468 | -106,264 | -87,934 | -1,212 | -53,258 |
Long-Term Debt Repaid | -2,290 | -92,263 | -94,201 | -201,593 | -91,675 |
Total Debt Repaid | -515,758 | -198,527 | -182,136 | -202,805 | -144,933 |
Net Debt Issued (Repaid) | 172,761 | 206,660 | -3,394 | 33,032 | 15,776 |
Issuance of Common Stock | - | - | 49,890 | - | 40,249 |
Dividends Paid | -8,075 | -7,741 | -7,278 | -8,066 | -6,458 |
Other Financing Activities | -334.23 | 1,702 | -0 | -9,450 | 656.41 |
Financing Cash Flow | 164,352 | 200,621 | 39,218 | 15,517 | 50,224 |
Foreign Exchange Rate Adjustments | -539.93 | 4,782 | -1,052 | 184.47 | 1,073 |
Miscellaneous Cash Flow Adjustments | - | 0 | -0 | - | - |
Net Cash Flow | 65,991 | -8,556 | 8,555 | 27,044 | 3,608 |
Free Cash Flow | -42,329 | -103,653 | 26,671 | 52,988 | 10,906 |
Free Cash Flow Growth | - | - | -49.67% | 385.84% | -85.36% |
Free Cash Flow Margin | -2.70% | -7.29% | 1.94% | 4.14% | 0.95% |
Free Cash Flow Per Share | -3678.75 | -9008.37 | 2334.47 | 4786.97 | 991.08 |
Cash Interest Paid | 23,615 | 23,084 | 16,604 | 11,480 | 9,839 |
Cash Income Tax Paid | 14,548 | 38,901 | 8,391 | 9,050 | 5,500 |
Levered Free Cash Flow | -98,628 | -174,863 | -18,388 | -44,864 | 44,982 |
Unlevered Free Cash Flow | -90,831 | -170,496 | -9,886 | -39,610 | 51,387 |
Change in Working Capital | -74,468 | -82,794 | -20,720 | 31,583 | -29,910 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.